Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders

• DOI: 10.1371/journal.pone.0284925
• Publication Date: 2023-05-01T17:24:15Z
• Authors: Hila Magen; Abraham Avigdor; Lee Nevo; Shalev Fried; Amit Gibori; Einav G. Levin; Yaniv Lustig; Eden Shkury; Galia Rahav
• Keywords: Antibody titer

Patients with plasma cell disorders (PCD) are at an increased risk for severe morbidity and mortality due to COVID-19. Recent data have suggested that patients hematological malignancies, including those PCD, suboptimal antibody response COVID-19 vaccination. We compared the titers of 213 PCD immunocompetent healthcare workers after second vaccine dose BNT162b2 mRNA vaccine. Blood samples were taken 2-4 weeks vaccination analyzed anti-receptor binding-domain immunoglobulin G (RBD-IgG) antibodies neutralizing (NA). At a median 20 days dose, 172 (80.8%) developed anti-RBD-IgG geometric mean titer (GMT) 2.7 (95% confidence interval [CI], 2.4-3.1). In control group 210 (98.9%) 21 days, GMT 5.17 (95%CI, 4.8-5.6), p<0.0001. NA observed in 151 MM (70.9%) controls (98.9%). The was 84.4 CI, 59.0-120.6), 420.2 341.4-517.1), respectively (p<0.0001). Multivariable logistic regression revealed number prior therapy lines age significant predictors poor humoral among MM. Injection site reaction, headache fatigue most common adverse events Adverse less than controls. conclusion, percentage protecting vaccine, which appears be safe this patient population.